Caio Júlio César Dos Santos Fernandes
Clinical trials sponsored by Caio Júlio César Dos Santos Fernandes, explained in plain language.
-
New study looks at Selexipag's Long-Term effects on rare lung condition
Disease control Not yet recruitingThis study looks at how well the oral medication selexipag works over the long term for people with a specific type of lung disease called schistosomiasis-associated pulmonary arterial hypertension. Researchers will compare patients who took selexipag with similar patients who di…
Sponsor: Caio Júlio César dos Santos Fernandes • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Rare lung disease treatment switch under review
Knowledge-focused Not yet recruitingThis study examines what happens when people with pulmonary arterial hypertension (PAH) switch from one medication to another as part of their triple therapy. Researchers will look at medical records from 15 adults to see if the switch improves walking distance, symptoms, and blo…
Sponsor: Caio Júlio César dos Santos Fernandes • Aim: Knowledge-focused
Last updated May 26, 2026 08:28 UTC